Cagrilintide
Long-Acting Amylin Analogue
Acylated amylin analogue designed for once-weekly subcutaneous dosing. Studied alongside semaglutide and retatrutide for combined incretin/amylin research. Available in 5 mg and 10 mg.
Fat Loss / Metabolic
Category
From $89.99
Price
Research
Grade
Price
From $89.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Titration-phase cadence is 0.25mg → 0.5mg → 1mg → 1.7mg weekly across 16 weeks, matching the REDEFINE phase 3 schedule. Total consumption over the titration phase is ~5-6mg — approximately one 5mg vial. After titration, researchers typically step to the 10mg format for maintenance at the 2.4mg weekly target dose.
This 5mg format is optimised for the titration phase of amylin-analog research protocols. The REDEFINE phase 3 program spends the first 16 weeks stepping doses through 0.25mg → 0.5mg → 1mg → 1.7mg before reaching the 2.4mg weekly target. Across those 16 weeks of titration, total cagrilintide consumption is roughly 5-6mg — almost exactly matched by a single 5mg vial. Researchers replicating the REDEFINE titration protocol specifically will consume the 5mg vial across the titration phase and then typically step to the 10mg format for the maintenance phase.
Reported Outcomes
5mg format — REDEFINE titration-phase-sized
Supports first 16 weeks of dose-escalation
Same long-acting fatty-acid-acylated amylin chemistry
Appropriate for pilot dose-tolerance work
Standard once-weekly subcutaneous dosing
Batch COA on identity and purity
Titration Sizing
Why 5mg Maps To 16 Weeks
The REDEFINE titration phase consumes roughly 5-6mg of cagrilintide across 16 weeks of step-up dosing — a coincidence that makes the 5mg vial an unusually natural fit for that phase of replication work. Once titration ends and weekly dosing stabilises at 2.4mg, consumption accelerates and the 10mg format becomes the appropriate maintenance vial.
Same Chemistry
Identical to the 10mg Molecule
The 5mg and 10mg cagrilintide vials contain the same fatty-acid-acylated amylin analog with the same ~7-day half-life and the same CTR/RAMP pharmacology. Format choice is a research-horizon decision matched to protocol phase, not a chemistry decision.
Pilot Use Case
Early GI-Tolerance Validation
Some researchers run short pilot protocols at 0.5-1mg weekly for 4-6 weeks specifically to validate GI tolerance before committing to a full REDEFINE replication. The 5mg vial is well-sized for this pilot work — enough material for the pilot window without committing to the full maintenance-dose supply chain.
Specifications
| Product | Cagrilintide |
|---|---|
| Category | Fat Loss / Metabolic |
| Format | Lyophilized powder |
| Price | From $89.99 |
Dosing Guide
Titration-phase cadence is 0.25mg → 0.5mg → 1mg → 1.7mg weekly across 16 weeks, matching the REDEFINE phase 3 schedule. Total consumption over the titration phase is ~5-6mg — approximately one 5mg vial. After titration, researchers typically step to the 10mg format for maintenance at the 2.4mg weekly target dose.
Cagrilintide — FAQs
Also Explore: Fat Loss / Metabolic
View All
Tesofensine 500mcg x30 Tablets
The pressed-tablet format — identical 500mcg tesofensine dose as the capsule variant, differentiated by faster GI disintegration kinetics and the practical option to split the tablet for lower-dose titration research.
Mazdutide 6mg
Mazdutide (IBI362) — Innovent Biologics' long-acting GLP-1/glucagon dual agonist, the oxyntomodulin analog licensed from Eli Lilly that received Chinese NMPA approval in 2025 for obesity and T2D.
Tesofensine 500mcg x30 Capsules
Tesofensine — a small-molecule triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) originally developed by NeuroSearch as an Alzheimer's candidate, reclassified into obesity research after Phase 2 showed 12.5kg mean weight loss at 1mg over 24 weeks.
